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ABSTRACT 
 
 
  
 This project investigated and described the impact of stem cells on society, as an example 
of the effects of technology on humanity.  This objective was met by closely examining stem 
cells, describing their various types, methods of isolation, medical benefits, and the ethical and 
legal issues surrounding their use.  Chapters 1 and 2 introduce stem cells and their use, while 
chapters 3 and 4 explore the ethical and legal issues with embryos and stem cell research.  Based 
on the research performed in the project, the authors conclude that adult stem cells should be 
used in lieu of embryonic stem (ES) cells whenever possible, that excess embryos from IVF 
reproductive clinics should be used for ES cell research rather than embryos from paid donors, 
and that funding should be increased for stem cell research. 
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PROJECT OBJECTIVES 
 
 
The purpose of this project was to investigate the field of stem cell science, describing the 
various types of stem cells, their potential uses in the field of basic science and medicine, and 
describing their effects on society via their ethics and laws.  Chapter-1 describes what stem cells 
are and their various types. Chapter-2 describes potential uses for stem cells in basic 
research and medicine, focusing on their benefit to mankind as a prelude to discussing their 
ethics.  Chapter-3 discusses the ethical issues related to the use of these cells.  Chapter-4 
addresses the legal issues surrounding the use of stem cells and embryos in research, and 
discusses the laws that regulate scientists who work in the stem cell field.   The project concludes 
with statements by the authors summarizing their own opinions on the controversial topic. 
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Chapter-1:  Stem Cell Types and Sources 
Ainaz Fathibitaraf 
 
 Stem cells are long lived cells with the ability to differentiate into various tissues.  
Because of this property, they form the basis of the new field of regenerative medicine, whose 
goal is to regenerate damaged or diseased tissues.  But in spite of this amazing regenerative 
capacity and potential benefit to society, stem cells are also one of the most controversial topics 
in science today, surrounded by ethical and legal issues.  The purpose of this chapter is to 
describe the various types of stem cells and their potencies, as a prelude to subsequent chapters 
on their applications, ethics, and laws. 
 
Stem Cell Properties 
All multi-cellular organisms contain a variety of cell types.  These cells are all derived 
from a single cell, the zygote, through processes of differentiation and proliferation. The 
differentiation process involves the selective activation and inactivation of genes that dictate the 
properties of that cell.  The newly fertilized egg divides for about 5-6 days until it forms a 
blastula or hollow ball of cells.  The blastula consists of an inner cell mass (ICM) and an outer 
layer of cells.  The inner cell mass is composed of embryonic stem (ES) cells, characterized by 
their undifferentiated state and their ability to divide for long periods of time.  When stem cells 
divide, either the division is symmetric (both daughter cells remain as stem cells) or asymmetric 
(one of the daughter cells remains a stem cell and the other daughter differentiates into a more 
specialized cell) (USA.gov, 2009).   
Stem cells retain the ability to develop into one or more cell types, depending on the type 
of stem cell (Figure-1).  Stem cell populations differentiate into various types of cells such as 
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red blood cells, muscle cells, or nerve cells, and play a role in replacing the damaged cells in the 
living organism (Library of Congress, 2010).  For example, skin stem cells are responsible for 
replacing the skin cells we are constantly losing, while muscle stem cells are involved in muscle 
repair and growth (Cordblood, 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Stem Cell Differentiation.  Stem cells are capable of division 
and renewal. They are unspecialized (un-differentiated) and have the 
ability to differentiate into specialized cells as shown in the figure.  
Embryonic stem cells are the most potent, and can differentiate into a 
variety of cell types including nerve, muscle, blood, and skin cells. 
(BioCat.com, 2011) 
 
 
Stem Cell Discovery 
The discovery of stem cells goes back to the 1800s when it was discovered that some 
cells have ability to produce other cells. During the 1900s, adult stem cells in bone marrow were 
first discovered.  Doctors eventually used these to treat leukemia and anemia. The first bone 
marrow transplant on humans was a bone marrow transplant in 1957 (Thomas et al., 1957).  
Human embryonic stem cell lines were first established in 1998 by James Thomson and his 
colleagues from the University of Wisconsin (Thomson et al., 1998) (Figure-2). In this 
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experiment, Thompson isolated ES cells from the inner cell mass of blastulas, and grew them on 
a feeder layer of irradiated (killed) mouse fibroblast cells.   
 
 
 
Figure-2:  Photograph of James Thomson.  Prof. Thomson is the 
American biologist who was the first to culture human embryonic stem 
cells from blastocyst embryos.  (University of Wisconsin-Madison 
News, 2008) 
 
 
 
 
Thomson’s method of preparing ES cell lines from blastocysts has become far more 
popular than the second method performed by John Gearhart (Figure-3) from John Hopkins 
University, who was the first to culture human ES cells from fetal germline tissue, a far more 
controversial source of tissue than blastulas (All About Popular Issues, 2011).  
 
                                                      
  
 
 
      
 
 
Figure-3:  Photo of John Gearhart.  Shown is the American 
biologist who first grew human embryonic stem cells from fetal 
primordial germ cells. (Academy of Achievement, 2010) 
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As will be discussed in detail in Chapter-2, stem cells have been valuable as research and 
therapeutic tools.  Researchers have been able to gain useful information concerning the 
signaling mechanisms involved in cell differentiation, and a better understanding of these 
processes will have great benefits in terms of cell-based therapies, which utilize stem cells to 
treat disease (USA.gov, 2009).  Stem cells from bone marrow have been used for decades to treat 
leukemia and other blood-related diseases. In recent years stem cell therapy has been used to 
treat other conditions, including heart disease, lung cancer, and stroke (Malliaras et al., 2001; 
Bang et al., 2005; Weiss et al., 2008).  Human stem cell experiments are based on animal 
models, such as mice, rats, and pigs. Although we are not yet at the stage where these treatments 
are widely available, it is likely that they will be in near future (USA.gov, 2009). 
 
Stem Cell Classification 
 Stem cells are generally classified as either embryonic or adult (somatic). Embryonic 
stem cells (ESC) occur during the early stages of development, notably the inner cell mass of the 
blastocyst.  During development, ESCs differentiate into all the various cell types found in an 
organism (Figure-4).  The embryos used to isolate ES cells are obtained from excess in vitro 
fertilization (IVF) embryos originally created for reproductive purposes.  
 
 
Figure-4: Differentiation of an Embryonic 
Stem Cell.  ES cells are pluripotent, and can 
form all the types of cells in the adult body.  
(Everts, 2007) 
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Adult stem cells (ACS) have been isolated from a variety of adult tissues, including 
muscle, brain, bone marrow, skin, heart, and bone. These cells are responsible for maintaining 
the various tissues in the body.  In general, ASCs are relatively rare cells within the adult tissues, 
and they are hard to isolate and grow (Garg, 2008).  So some scientists prefer working with ES 
cells as they are relatively easy to isolate and grow.  Table-I lists examples of ASCs and the cell 
types into which they differentiate.  Adult stem cells, unlike ESC, are restricted in their potency, 
and can differentiate into fewer types of cells than ES cells.  Although ASCs have significant 
drawbacks, their use does not destroy an embryo, so they have fewer ethical concerns.  In 
addition, ASCs can be isolated from and used in the same individual, dramatically reducing the 
possibility of immune rejection (Garg, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-I: Example of Various Adult Stem Cells and their Differentiation. 
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 Another type of stem cell is the induced pluripotent stem (iPS) cell.  These cells represent 
adult somatic cells, such as a skin fibroblast cell, reprogrammed into a pluripotent like state.  
Because no embryos are involved, and they appear to be pluripotent, scientists are excited about 
their possibly replacing ES cells in the future.  A variety of somatic cells, including fibroblasts 
and neural stem cells, have been reprogrammed into de-differentiated embryonic-like stem cells 
by either transfecting specific genes into the cells or their proteins.  The reprogramming is 
performed by transcription factors that help maintain the pluripotent like state.   
 iPS cells were discovered in Yamanaka’s lab in Japan, and were first induced from 
mouse skin fibroblast cells (Takahishi et al., 2006) and then from human skin fibroblast cells 
(Takahashi et al., 2007).  Initially, four transcription factor genes were used to perform the 
reprogramming: Oct3/4, Sox2, c-Myc, and Klf4.  But later experiments indicated the presence of 
the c-Myc component induced tumor formation at the injection site, so that component was later 
omitted.  Viruses were also used to deliver the genes, but due to worries about gene integration 
later experiments left out the viruses and just delivered the transcription factor proteins 
themselves.  In the initial experiments to derive human iPS cells, the scientists reprogrammed 
fibroblasts from the facial skin of a 36 year old woman and from a 69 year old man (Takahashi et 
al., 2007). 
 These iPS cells have been a valuable advancement because of the relative ease of 
obtaining somatic cells and the elimination of the ethical issues surrounding embryo-derived ES 
cells. Scientists are still trying to prove exactly how potent these cells are, as some scientists 
claim the cells are more likely to have DNA mutations (Gore et al., 2011).  Although the 
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techniques used to reprogram somatic cells are challenging, this technology hopefully will prove 
to be a great value to stem cell research.  
 
Stem Cell Potencies 
Stem cells are also commonly classified based on their potency, a measure of a stem 
cell’s ability to differentiate into different cells (Figure-5). Cells capable of differentiating into 
all cell types, including the extra-embryonic tissues (e.g. placenta) of a developing organism are 
considered totipotent. The only cells with this level of potency are the zygote, or fertilized egg 
and cells through the eight-cell stage of development. The next level of potency, pluripotent, 
includes the ESCs mentioned earlier, which have the ability to differentiate into a wide variety of 
cell types of the body.   
 
 
 
 
 
 
 
 
 
Figure-5: Diagram of the Major Categories of Stem Cell Potencies.  
Totipotent refers to a zygote through the 8-cell stage.  Pluripotent cells 
are derived from the blastocyst and are exemplified by embryonic stem 
cells.  Multipotent and unipotent cells have a more limited capacity to 
differentiate.  Curved arrows indicate the ability of the cells to 
perpetuate. 
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Cells considered lower than pluripotent but higher than multipotent are the three primary 
germ layers, the ectoderm, mesoderm and endoderm, which together differentiate into all the cell 
types found in an adult (Figure-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: Differentiation of Ectoderm, Endoderm, Mesoderm Cells.  
Zygote division eventually leads to gastrulation and the formation of 
three germ cell layers: ectoderm (exterior layer), endoderm (inner layer) 
and mesoderm (middle layer). Together all three of these embryonic 
layers form all the tissues of the adult body.  The ectoderm forms the 
nerves system and epidermis. Endoderm forms the epithelial lining. 
Mesoderm forms the mesenchyme, mesothelium and coelomocytes.  
(Loyola University, 2011) 
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Multipotent stem cells are less potent than ES cells.  These cells form a few types of 
related cells.  Examples include hematopoietic stem cells, which produce several kinds of blood 
cells, and neuronal stem cells which are responsible for the production of neuronal cells and 
neuroglial cells (Library of Congress, 2010).  Unipotent stem cells are the least potent in terms of 
their ability to differentiate.  These cells are able to make only one type of cell, usually the same 
as the tissue they are isolated from.  For example, skin stem cells usually form only other skin 
cells.  
Stem cell research is still ongoing and holds great potential.  The study of stem cells will 
help scientists determine the complex signaling involved in the differentiation process, will allow 
the production of cell lines from patients with specific diseases, and will hopefully allow 
regenerative therapies to treat diseases (USA.gov, 2009).  
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Chapter-2: Stem Cell Applications 
Michael Gauvin 
 
 
 After discussing the various types of stem cells in the previous chapter, attention is now 
turned towards discussing how stem cells are used.  This topic is important for understanding 
their benefits to society which are strongly weighed in discussions of stem cell ethics.  This 
chapter describes four specific examples of the use of stem cells to treat diseases. 
 
Leukemia and Stem Cells 
 
The most practiced application of stem cells is the use of hematopoietic stem cells in 
treating leukemia.  Each year in the United States, “more than 40,000 adults and 3,000 children 
develop this cancer of the blood cells” (Panno, 2010, pg. 99).  This disease affects a type of 
white blood cell known as a lymphocyte that produces antibodies and plays a major role in the 
immune response.  Mutations in the DNA of lymphocytes leads to a lack of maturation, so 
immature, non-functional lymphocytes accumulate in the bloodstream.  Lymphocytes are derived 
from the process of hematopoiesis (Figure-1) from bone marrow stem cells.  Treatment for 
leukemia patients usually includes radiation and chemotherapy to kill the cancerous lymphocyte 
cells, and in extreme cases involves the complete destruction of the patient’s own bone marrow.  
The result of this process requires a bone marrow transplant from a compatible donor to replace 
the destroyed bone marrow (Panno, 2010, pg. 99-101).   
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Figure-1:  Diagram of Hematopoiesis.  Shown are bone marrow 
derived stem cells and their potential to differentiate into the 
cellular components of blood, including lymphocytes. (NIH, 2006) 
 
 The process of using stem cells from bone marrow is by no means a new practice.  In 
fact, “In 1956, three laboratories demonstrated that injected bone marrow cells directly 
regenerated the blood-forming system, rather than releasing factors that caused the recipients’ 
own cells to repair irradiation damage” (NIH, 2006).  Injection of HSCs is still the only known 
method to repair hematopoietic failure after radiation.  Radiation treatments to kill rapidly 
dividing cancer cells began in the early 1960’s (NIH, 2006), and is still in use today. 
 The success of bone marrow transplants is strongly related to the ability of the graft to 
survive, which is related to donor-recipient histo-compatibility.  Acceptable donors for the bone 
marrow include close family relatives, such as parents and siblings, but graft-versus-host-disease 
(GVHD) can still remain a major threat. “Rates of GVHD vary from 30-40% among related 
donors and recipients, and from 60-80% for unrelated donors and recipients” (Hoffman et al., 
2008.).  Stem cell therapy can sometimes resolve GVHD problems by obtaining the cells from 
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the donor themselves.  Bone marrow cells are taken from the patient, and attempts are made to 
isolate healthy from cancerous hematopoietic stem cells (HSCs).  The HSCs are grown in 
culture, tested for known leukemia-causing DNA mutations, and inserted back into the patient to 
replace the marrow destroyed by chemotherapy (Panno, 2010, pg. 99-101). 
 In the past decade, new sources of hematopoietic stem cells have been investigated.  
Umbilical cord blood is highly enriched for HSCs, and because they are more primitive than 
bone marrow isolated HSCs they appear to induce less GVHD (Viacell, 2011).  In addition, a 
recent discovery by researchers at the University of California Santa Cruz may make the 
harvesting of a patient’s own stem cells even easier.  A molecule named Robo4 binds stem cells 
to bone marrow, so its elimination might allow for stem cells to be easily taken from the blood 
stream, instead of using injections of cytokine hormones to induce their release which produces 
side effects.  According to study leader Camilla Forsberg, “If we can get specific and efficient 
inhibition of Robo4, we might be able to mobilize hematopoietic stem cells to the blood more 
efficiently” (Stephens, 2011).  Further study of this molecule may also allow for easier expansion 
of the HSCs in culture. 
 
Diabetes and Stem Cells 
 
Diabetes is a disease that affects seven percent of the world’s population, and is projected 
to rise to over 380 million people by 2025 (NIH, 2006).  It is a metabolic disorder that inhibits 
the body’s ability to make proper use of glucose, a large energy source for living cells.  For 
Type-I diabetes, the problem arises in the pancreas (Figure-2), where insulin-producing β-cells 
lose their ability to function.  Insulin is a hormone that stimulates the uptake of glucose from the 
blood into cells.  A decrease in insulin production results in a buildup of glucose in the 
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bloodstream which can eventually lead to blindness, heart disease, stroke, kidney failure, and 
amputations (Panno, 2010, pg. 93-95).   In type I diabetes, often called juvenile diabetes as it 
usually occurs at a younger age, the patient’s white blood cells attack the pancreatic β-cells 
eventually destroying the body’s ability to produce insulin and break down glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2:  Diagram of a Healthy Human Pancreas.  The pancreas 
(upper left) contains the Islets of Landerhans (upper right) that contain β-
cells (lower right).  The β-cells produce insulin that allows cells to take 
up glucose from the blood (lower left).  (NIH, 2006) 
 
 
 One of the first major breakthroughs in treating diabetes with stem cells came in 2000, by 
the Institute of Bioengineering at the University Miguel Hernandez (Soria et al., 2000).  The 
team was able to differentiate mouse embryonic stem (ES) cells in vitro to become insulin-
producing cells.  After the cells were implanted in the spleen of streptozocotin-treated diabetic 
mice, their hyperglycemia was corrected in one week, and their weight normalized after four 
weeks.  The study showed that a mouse model of diabetes could be treated with mouse ES cells, 
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and suggested that there is major potential in this process for those afflicted with type-1 diabetes 
(Soria et al., 2000).   
Research with human embryonic stem (hES) cells soon followed, and by 2001 
researchers found, “Using hES cells in both adherent and suspension culture conditions, we 
observed spontaneous in vitro differentiation that included the generation of cells with 
characteristics of insulin-producing β-cells…. These findings validate the hES cell model system 
as a potential basis for enrichment of human β-cells or their precursors, as a possible future 
source for cell replacement therapy in diabetes” (Assady et al., 2001). Lumelsky et al. (2001) 
also showed the potential of human ES cells to differentiate in vitro into insulin producing cells.  
A similar study was performed in 2006 when Novocell Inc. induced hES cells to become 
pancreatic hormone-expressing endocrine cells.  The cells are “capable of synthesizing the 
pancreatic hormones insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin” 
(D’Amour, 2006).  Novocell tested these β-cell precursors in mice with interesting results.  “The 
cells did not colonize the pancreas, but did produce insulin, and appeared to respond to normal 
physiological cues” (Panno, 2010, pg. 93-95).  This experiment shows that the cells do not 
necessarily have to assimilate within the pancreas to produce insulin. Kroon et al. (2008) 
extended these experiments to show that human ES cells can be used to treat mouse models of 
diabetes.   The use of human ES cells to treat diabetes has not made it to human clinical trials 
due to the fact that 7% of the treated mice appeared to develop cancerous tumors from the 
implanted cells.  So this problem must first be solved before using ES cells to treat diabetes. 
Efforts to direct the differentiation of adult stem cells (ASCs) and induced pluripotent 
stem (iPS) cells into β-cells are still being studied.  In mice, adult pancreatic cells have been 
reprogrammed to secrete insulin (Zhao et al., 2008), and iPS cells have successfully been used to 
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treat mouse models of diabetes in vivo (Alipio et al., 2010).  However, most scientists believe 
that ES stem cells offer the best cure for diabetes.  “Harvard University researcher Douglas 
Melton… pointed out that in mice, new β-cells in the pancreas are normally formed through the 
replication of existing β-cells rather than through the differentiation of adult stem cells. 
 
Cardiovascular Disease and Stem Cells 
 
According to the World Health Organization (WHO) cardiovascular disease is the 
number one cause of death worldwide, killing over 17 million people.  This number is projected 
to rise to over 23 million by the year of 2030, with the majority of deaths occurring from heart 
attacks (WHO, 2011).  Heart attacks result from an obstruction of blood supply to the heart 
which can lead to the death of cardiac muscle.  Varying degrees of damage to the heart muscle 
cells (cardiomyocytes) range from minor inability to pump blood effectively, to complete failure 
of the organ (Panno, 2010, pg. 93-95).  Stents and by-pass surgeries are sometimes successful 
with some patients, but organ transplant remains the only treatment for complete cardiac failure, 
a procedure that is both dangerous and extremely expensive.  According to Transplant Living, as 
of 2007 the average total cost of a heart transplant was $787,700, with the possibility of organ 
rejection and a life of anti-rejection medications still ahead of them (Transplant Living, 2011). 
Stem cell therapies to treat this disease would be one of the greatest advancements in 
medicine to date.  Among the first attempts to use stem cell therapy to treat cardiac failure was 
done by researchers at the National Institutes of Health (NIH) in 2001.  The team induced heart 
attacks in mice and injected them with adult stem cells extracted from mouse bone marrow.  
“The researchers found that newly formed myocardium occupied 68% of the damaged portion of 
the ventricle nine days after transplanting the bone marrow cells.  The developing tissues 
appeared to consist of proliferating cardiomyocytes and vascular structures” (Panno, 2010, pg. 
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89-92).  This experiment was soon extended by Kocher et al. (2001) who used human bone 
marrow-derived stem cells to treat mouse models of ischemia. 
These impressive animal results with bone marrow stem cells led to over 30 Phase I 
human clinical trials for cardiovascular disease by 2008.    One of the most promising studies 
came with the implantation of skeletal myoblasts into akinetic/dyskinetic area of the damaged 
heart (Siminiak et al., 2004).  The results of the procedure were interesting.  “The left ventricular 
ejection fraction increased from 25% to 40% (mean, 35.2%) before the procedure to 29% to 47% 
(mean, 42.0%) during the 4-month visit (P <.05), and the improvement was maintained 
throughout 12 months of follow-up” (Siminiak et al., 2004).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3:  Diagram of Treating Heart Attacks with Stem Cells.  
Scientists have tested the injection of mouse bone marrow stem cells 
delivered directly into the heart (upper left) and human bone marrow 
stem cells injected into the tail vein (upper right).  The former procedure 
led to a 68% regeneration of the damaged tissue. (NIH, 2011) 
 22 
 
The initial success using skeletal myoblast cells in human patients by Siminiak et al. 
(2004) was followed in 2006 by treatment of patients with bone marrow-derived stem cells 
(Lunde et al., 2006; Schächinger et al., 2006). 
Others believe that these adult stem cell treatments hold much less potential than ES cell 
treatments.  According to Professor Joseph Panno, the procedures with injections of the patient’s 
own bone marrow-derived stem cells seemed to provide little improvement in cardiac function. 
Although the cells expressed some key marker transcription factors of cardiac cells, they did not 
appear to restore function strongly (Panno, 2010, pg. 90).  He believes the small improvements 
were “likely due to factors released by the transplants.  Thus, some scientists believe ES cells 
have the most long term potential for treating cardiovascular disease.  Researchers such as Izhak 
Kehat have had success in differentiating human ES cells into cardiomyocytes.  According to a 
2001 article, “the human ES cell–derived cardiomyocytes displayed structural and functional 
properties of early-stage cardiomyocytes. Establishment of this unique differentiation system 
may have a significant impact on the study of early human cardiac differentiation, functional 
genomics, pharmacological testing, cell therapy, and tissue engineering”(Kehat et al., 2001). 
However, ES cells have their drawbacks.  In addition to their ethical issues, graft-versus-host 
disease (GVHD) is always a threat as the cells would be allogeneic, derived from someone other 
than the patient themselves. And the development of teratomas is also a possibility.  This occurs 
when not all of the injected cells integrate with the cardiomyocytes, so they migrate elsewhere, 
triggering tumor formation.  
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Parkinson’s Disease and Stem Cells 
 
 Parkinson’s disease (PD) is a neurodegenerative disease that affects an estimated four to 
six million people world-wide (National Parkinson’s Foundation, 2011).  The disease attacks the 
neurons in the substantia nigra which produces dopamine (Figure-4).  The loss of dopamine 
affects neuromuscular transmission, causing tremors, muscular stiffness, and balance (Panno, 
2010, pg. 107, 108).   
 
 
 
 
 
 
 
 
 
Figure-4:  Brain Areas Affected by Parkinson’s Disease.  This figure 
shows the effect of Parkinson’s disease on the substantia nigra which 
secretes dopamine neurotransmitter.   (Medline Plus, 2011) 
 
 
Stem cell therapy might be a treatment for this disease because the damage is isolated to 
one area of the brain. Some of the first attempts to treat human Parkinson’s patients with cell 
therapy were performed in 1988, treating PD patients with fetal tissue implants obtained from 
aborted fetuses (Madrazo et al., 1988).  In 1998, implantation of neurological precursors was 
studied in an effort to produce dopaminergic neurons (the neurons which populate the substantia 
nigra).  According to an article published by Nature Neuroscience, “CNS precursor cell 
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populations expanded in vitro can efficiently differentiate into dopaminergic neurons, survive 
intrastriatal transplantation, and induce functional recovery in hemiparkinsonian rats” (Struder, 
1998).  This groundbreaking procedure gave great promise to the use of neural stem cells (NSCs) 
to eventually cure Parkinson’s in humans. 
In 2004, scientists showed that human ES cells could be differentiated into midbrain 
neurons capable of producing dopamine (Perrier et al., 2004).  A paper was published in 2009 on 
the use of these NSCs to treat a Parkinson’s patient by neuroscientist Steven Ertelt.  According to 
Ertelt, "We have documented the first successful adult neural stem cell transplantation to reverse 
the effects of Parkinson’s disease, and have demonstrated the long term safety and therapeutic 
effects of this approach."  The group extracted the NSCs from a PD patient, expanded them in 
vitro, induced them to become mature dopaminergic neurons, and finally injected them back into 
the affected part of the patient’s brain (Ertelt, 2009).  The results of the procedure produced 
impressive results.  The patient sustained an 80% increase in his motor skills, sustained for at 
least 5 years after the surgery (Ertelt, 2009).  The procedure produced no tumors, a problem that 
often arises after ES cell implantations.  It is also important to note that the stem cells used were 
derived from the patient himself, lowering the possibility of rejection.  Thus, for this application 
of treating Parkinson’s disease, the use of adult stem cells appears to have more promise than 
using ES cells, as it eliminates most of the ethical issues while producing no tumors. 
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Chapter-3:  Stem Cell Ethics 
Michael Gauvin 
 
After discussing the various types of stem cells and their uses in previous chapters, 
attention is now turned to whether such cells should be researched.  The discussion of stem cell 
ethics weighs the balance between the benefit to society (discussed in chapter-2) versus the 
destruction of the embryo (for embryonic stem cells).  The views of some of the major world 
religions will be used as an outline for investigating when life begins and the status of the human 
embryo. 
 
Adult Stem Cell Ethics 
Contrary to popular belief that religions do not support the use of “stem cells”, most of 
the world’s major religions support the use of adult stem cells to save human lives (Pope 
Benedict XVI, 2008).  Adult stem cells (ASCs) do not destroy embryos during their isolation.  
Promising advances in ASC and induced pluripotent stem (iPS) cell research may someday put 
an end to the ethical issues of using ES cells.  However, medically there are some drawbacks to 
using ASCs.  As pointed out in Chapter-2, ASCs do not appear to work well for some types of 
diseases, including heart attacks.  ASCs do not appear to be able to differentiate into as many 
tissues as ES cells, they are harder to isolate and harder to grow (NIH, 2006).  Thus, whenever 
possible, scientists continue to work with ES cells. 
 
 
 
 28 
Embryo Ethics 
With respect to embryonic stem (ES) cells, the ethical debate focuses on the status of 
human embryos.  As discussed in Chapter-1, ES cells are isolated from the inner cell mass of 5-
day old IVF blastocysts which are usually destroyed in the process.  So the debate focuses on 
when life begins relative to the 5-day old blastocyst.  Is it murder to harm this embryo?   
A document called the Belmont Report is an extension of the Hippocratic Oath, and 
provides ethical guidelines to physicians.  The Hippocratic Oath states, “I will give no deadly 
medicine to anyone if asked, nor suggest any such counsel” (Panno, 2010).   Thus, physicians 
cannot harm their patients in their research even if it may benefit another.   The Belmont Report 
also adds two extra components:  1) the idea of informed consent requires written consent from a 
research subject before any trials can be done, and 2) the idea of a patient’s advocate who makes 
sure any research is explained clearly to the test subject.  With respect to ES research, many 
ethicists believe that the Belmont report suggests  that “a human embryo or fetus, incapable of 
giving informed consent, should be afforded the benefit of an advocate” (Panno, 2010).  If this is 
true we can clearly see how important the question of the beginning of life becomes. 
 
Religions and ES Cell Ethics 
Religions can provide a framework for the question of when life begins.  We will see 
how this question of the beginning of life greatly affects the viewpoints of these groups on the 
subject of embryos and ES cells.  For example, some religions believe that ensoulment occurs at 
the moment of conception, and from that point on the embryo has the rights of any other living 
person.  Other religions disagree with this idea, and believe the embryo is a soulless, unconscious 
entity until at least the fortieth day of development.   And some religions give weight to whether 
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the stem cell experiments are performed to increase longevity and improve the quality of life of 
the human race.  Some religions believe that it is their duty to solve problems in the world.  We 
will see how religions must balance their embryo beliefs with their desire to improve human life. 
 
Catholics and Stem Cells 
Many are aware that the Catholic faith believes that the destruction of the embryo for any 
means is seen as deliberate murder of a human being.  The Congregation for the Doctrine of the 
Faith issued a statement in February 22, 1987, known as the Donum Vitae, which states that the 
“human being is to be respected and treated as a person from the moment of conception and 
therefore from that same moment his rights as a person must be recognized” (Shannon 2002).  
The Catholic belief that life begins at conception is a major contributor to opposition to ES cell 
research.  Pope John Paul II gave his opinion on the matter in 2001 in response to President 
Bush’s decision to allow federal government funding for 64 stem cell lines: 
“Experience is already showing how tragic coarsening of 
consciences accompanies the assault on a human life in the womb, 
leading to accommodation and acquiescence in the face of the 
related evils such as euthanasia infanticide and, most recently, 
proposals for the creation for research purposes of human embryos, 
destined to be destroyed in the process.”  (Wagner, 2008) 
 
 
Judaism and Stem Cells 
The Jewish interpretation of religious texts leads to a very different stance on the issue of 
stem cells.  Many Jews believe they have a responsibility to repair the broken world, a concept 
known as Tikkun Olam.  According to Jewish ethicist Eliot Dorf, “The potential of stem cell 
research for creating organs for transplantation and cures for diseases is, at least in theory, both  
awesome and hopeful.  Indeed, in light of our divine mandate to seek to maintain life and health, 
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one might even contend that from a Jewish perspective we have a duty to proceed with that 
research.”   
 The Jewish religion also does not see conception as the starting point of human life.  The 
Talmud, a central text in Judaism, states that an embryo is “mere fluid” until forty days after 
conception (Bennet, 2011).  There is also a popular Jewish belief that embryos outside the 
womb, such as leftover embryos from IVF, do not have the potential to become human beings.  
Therefore the destruction of an early embryo is not looked at as infanticide as it is in the Catholic 
religion, and Jewish ethicists see these entities as great opportunities for human healing 
(Yearwood, 2006). 
 There is however, some disagreement in Judaism in the case of creating embryos solely 
for research purposes versus using excess IVF embryos.  Dorff himself, a proponent of stem cell 
research, said, "creating an embryo specifically to be the source of stem cells is permissible, but 
less morally justifiable.”  Others such as Rabbi Aaron Mackler, a conservative expert in bioethics 
and Jewish law, believes that, “There is potential life… and we need to respect that and be 
cautious” (Yearwood, 2006).  
 
Islam and Stem Cells 
 Islam theology has a similar stance to that of Judaism on the issue of stem cell research.  
Ethicists of this religion use the Qur’an, the main authority of Islam to determine the standing of 
the embryo, “We created man of an extraction of clay, then we sent him, a drop in a sage 
lodging, then we created a drop of clot, then we created a clot of tissue, then we created the 
tissue of bones, then we covered the bones in flesh; thereafter we produced it as another creature. 
So blessed be God, the best of creators (Chapter 23, verse 12-14).”  Some believe this passage 
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implies an embryo is not alive until at least 40 days of development.  Others believe that 
ensoulment does not occur until one hundred and twenty days after conception. based on this 
passage: The embryo exists forty days as a drop of matter, forty days as a blood clot, and forty 
days as a blob until an angel breathes life into it (Weckerly, 2006).  The blastocyst is not 
considered a human being at conception as in Catholic belief, and its destruction is not seen as 
“murder”.  This belief makes Muslims much more likely to be supporters of ES cell research. 
 Another factor that leads Islamic ethicists to be proponents of this research is the 
importance of inheritance rights and the prohibition of surrogate parenting.  For example, if a 
Muslim were to choose IVF they would want the excess embryos destroyed. This would 
eliminate the possibility of future children with their genetic information from a surrogate 
mother to claim inheritance.  However, rather than wasting excess IVF embryos, some Muslims 
choose to donate their zygotes to laboratories (Bennet, 2011).  
 
Hinduism and Stem Cells 
 The religion of Hinduism contains a firm belief that all life is sacred whether it is plant, 
animal, or human.  There is however, a hierarchy in this system, and followers of the religion 
know they have to consume to survive.  This hierarchy is based on the level of consciousness of 
the organism: where humans are on the top, below which are animals, and the lowest level 
contains plant life.  In Hinduism, the soul is reincarnated throughout a number of different 
species until it reaches its highest level of consciousness, human life.  The final step after being 
born human is ending the cycle of reincarnation and uniting with God.  Hindus put great 
importance on extending the longevity of life as it would allow them more time to become closer 
to God and break this reincarnation cycle.  They believe that using unconscious embryos to 
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improve the overall quality of life of a conscious human life is absolutely morally acceptable 
(Bahnot, 2008). 
 
Buddhism and Stem Cells 
 Traditional Buddhist teachings seem to contradict one another on the matter of stem cell 
research, which clouds the waters on the subject.  Buddhists place a very high prominence on the 
virtue of knowledge, which they call “prajna”.  This, along with the importance of compassion, 
“karua”, would lead one to believe that they would welcome ES research as it would provide 
them with great knowledge and help alleviate a large amount of human suffering.  The problem 
arises when one considers the belief of continual rebirth, and the fact that Buddhists believe that 
life starts at conception.  The newly formed embryo is given the same moral status as a recently 
deceased individual, which is seen as equal to that of a living being.   The idea of “ahimsa”, the 
protection of living things, makes the concept of embryonic stem cell research morally 
impermissible (Keown, 2004). 
 
iPS Cell Ethics 
 Induced pluripotent stem (iPS) cells are adult somatic cells reprogrammed to have some 
of the same potential as embryonic stem cells.  From an ethical standpoint, iPS cells avoid many 
of the problems that ES cells face, as no embryos are destroyed.  iPS cells steer clear of this 
problem because the cells are derived from an ordinary human skin fibroblast cell.  The skin 
cells are treated with a virus vector or proteins that reprogram the cells to a state of pluripotency. 
This also solves the problem of possibly harming female donors as eggs are not needed for the 
process (NIH, 2006).   
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 However, some scientists argue that iPS cells are harder to grow than ES cells, and may 
contain cancer-causing DNA mutations (Doglin, 2010).  And some scientists argue iPS cells may 
not be truly pluripotent.  Thus, more research is required to determine their true potency and 
whether their use causes cancer.  Another problem that may arise in the future is the prospect of 
creating human life from iPS cells if they are ever shown to be totipotent.  If it is possible to 
create a totipotent cell from these chemically reprogrammed skin cells, it may be possible to 
create a living being from them, which constitutes reproductive cloning.  If this is accomplished, 
a number of legal and ethical problems would emerge, as stated by Timothy Caulfield of the 
University of Alberta's Health Law Institute: 
 "From a legal perspective, iPS technology is fascinating and complex.  For 
example, if an iPS cell can be made into a functional human gamete, the potential 
exists for reproductive purposes. What would this mean for donor consent, 
concerns about cloning and rights of a potential child to know its parents….What 
could this mean to assisted reproduction practices and would-be parents with no 
other option?  If anything, we know considerable thought and policy development 
needs to be placed around these and other issues." (University of Alberta, 2009) 
 
 
Author Conclusion on Embryo Use 
 The author of this chapter is not against the use of embryos in stem cell research under 
any circumstances.  I offer you an analogy from Michael J. Sandel: 
“Although every oak tree was once and acorn, it does not follow that acorns are 
oak trees, or that I should treat the loss of an acorn eaten by a squirrel in my front 
yard as the same kind of loss as the death of an oak tree felled by a storm.  
Despite their developmental continuity, acorns and oak trees differ.  So do 
humans embryos and human beings, and in the same way. Just as acorns are 
potential oaks, human embryos are potential human beings. 
The distinction between a potential person and an actual one makes a moral 
difference. Sentient creatures make claims on us that consentient ones do not; 
beings capable of experience and consciousness make higher clams still. Human 
life develops by degrees.”  (George, 2005) 
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The stage of the embryo is very important to note.  In 1994, the Report of the Human 
Embryo Research Panel (HERP) stated that, “protectability is not an all-or-nothing matter but 
results from a being’s increasing possession of qualities that make respecting it more 
compelling” (NIH, 2006). This view has been around for thousands of years and was even shared 
by the Greek philosopher Aristotle who believed that life develops through three stages: 
vegetative, animate, and intellectual.  The first two stages were completed in the womb, but the 
final stage comes only after developing an intellect and collected experience.  An interesting 
thing to consider when looking at this subject is the fact that parents would be much more likely 
to grieve the loss of their newborn child rather than the death of an embryo through miscarriage.  
Thus, in the author’s view, a 5 day old blastocyst with the potential for life does not have the 
same status as a living being. 
When accessing the ethics of stem cell research, one of the most crucial areas to consider 
is the individual identity of the embryo.  This individual identity is necessary for the embryo to 
have moral rights.  At the point of about 5 days after conception, this embryo is merely a group 
of undifferentiated cells with no consciousness or experience (Lindsay, 2006).   If we were to 
treat this entity with the same rights as a fully developed human we would be forced to treat each 
cell in the human body with the same rights.   
 The phenomenon of twinning also provides some other problems with the theory of 
personhood at conception.  It is possible for the embryo to divide and develop into a separate 
human being until the third week of development.  From this evidence we can conclude that 
there is no determinate individual at the moment of conception.  We can also argue that because 
twins are not completely identical to each other, the embryo is not necessarily identical to the 
humans they develop into (Lindsay, 2006).  One could pose an interesting argument with the fact 
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that twins have different points of origin: if it is true that all persons exist at the moment of 
conceptions, does that then mean that one of every set of twins is not human? 
 Some argue that leftover embryos should not be used for stem cell research as they were 
originally developed for the purpose of creating life.  I think this view may come from a lack of 
understanding of the process of in vitro fertilization.  Embryos have no potential to become a 
human until they are implanted into a woman’s uterus.  As stated by Ronald A. Lindsay, “Their 
potential is no more than a theoretical construct.” These embryos will simply be kept in frozen 
storage and eventually be discarded if not used.  According to James Thomson developmental 
biologist at Wisconsin University, “There are over 400,000 frozen embryos in the United States, 
and a large percentage of those are going to be thrown out.… It’s a better moral decision to use 
them to help people” (Lindsay, 2006)  It seems to me that it is unethical if we do not take 
advantage of these frozen embryos, as they have great potential to save lives and would 
otherwise be wasted. 
 I am also in favor of using embryos created solely for the purpose of research because 
these do not have the potential to become human, and to me this resolves a major ethical 
question the subject is faced with.  For example, in somatic cell nuclear transfer (SCNT) there is 
no sperm-egg fertilization.  Instead, a somatic cell nucleus is inserted into an egg cell and an 
electrical trigger causes it to begin dividing.  We see here that there is absolutely zero potential 
for this blastocyst to become a living being unless it is intentionally implanted into a human 
uterus (Lindsay, 2006).   SCNT also serves as a method to disprove the “argument from 
potential”.  “Through SCNT, a somatic cell is allowed to express its potential to be transformed 
into an embryo that is latent in its genes but has been suppressed.  If gene-based potential to 
develop into a person is sufficient to provide an entity with full moral status, then each somatic 
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cell in a human person’s body has the same rights as the person herself” (Lindsay, 2006).  I 
personally find this conclusion to be completely unacceptable.  Treating each cell in the human 
body with the same rights as the person from whom it was derived would deem much of modern 
medicine immoral.  
 I am in favor of using adult stem cells instead of embryonic stem cells if they can 
produce the same medical results.  So far, ES cell research is proving to have much more 
potential than ASCs.  ASCs are much less versatile, and cannot differentiate into as many 
different types of cells.  ASCs are also not as easy to grow in culture compared to ES cells.  One 
positive to the use of ASCs is that they are much less likely to be rejected by the patient due as 
they are derived from the patients themselves (NIH, 2006).  This type of graft, known as an 
autologous graft, would relieve the patient of a life taking anti-rejection medication and the 
possibility of graft-versus-host disease (GVHD) (NIH, 2006).  Because ASCs resolve the major 
ethical issue of ES cell research, I encourage their use whenever possible.  I would however, 
rather see more federal funding for ES cell research, as I believe it holds much more promise. 
 I am also in favor of using iPS cells for many of the same reasons.  Although iPS cells 
still require much further research to determine their true level of potency and to determine 
whether they carry DNA mutations, I believe they have great potential.  Like ASCs, iPS cells 
avoid many of the ethical problems of ES cells because they are derived from adult somatic cells, 
leaving the question of the beginning of life and the concept of murder out of the debate.  One of 
the only remaining ethical issues would be the possibility of creating life from iPS cells if they 
are even shown to be totipotent, however this has not occurred.  iPS cells are also thought to 
have an extremely low rejection rate, as they can be derived from adult skin cells taken from the 
patients themselves and reprogrammed for transplantation (NIH, 2006).  I believe iPS cells 
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should be used whenever possible, as they resolve the ethical issues of ES cells.  However, I do 
not share the view that ES cell research is wrong, and likewise believe that the majority of 
research should be focused in that area. 
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Chapter-4: Stem Cell Legalities 
Hashim Ismail 
 
Stem cells, and in particular those derived from human embryos, bring both controversy 
and promise. Since the first successful isolation of human embryonic stem cells (hESCs) by 
James Thomson of the University of Wisconsin in 1998 (Thomson et al., 1998), these cells have 
risen to become one of the hottest and most controversial subjects of the 21
st
 century.  hESCs are 
unspecialized, nature’s master cells that can divide into any of the more than 200 specialized 
cells of the body.  From various religious beliefs, to political and humanitarian arguments, this 
subject has caught the attention of renowned leaders of our era. These cells are believed to hold 
cures for a myriad of deadly diseases ranging from cancer to neurodegenerative and heart 
diseases.  
But does this medical benefit to society grant us the permission to destroy human 
embryos?  hESCs are isolated from the inner cell mass of a 5-day old embryo prepared by in 
vitro fertilization (IVF).  Addressing an international congress in 2008, Pope Benedict XVI noted 
“the destruction of human embryos to harvest stem cells is "not only devoid of the light of God 
but is also devoid of humanity" and "does not truly serve humanity" (Catholic Online, 2008). The 
stem cell ethics debate (discussed in Chapter-3) is reflected in the complex assortment of laws 
regulating stem cell and embryo use in various countries.  This chapter will discuss current 
federal and state regulations of the US, as well as international laws governing stem cell 
research.  
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Early US Embryo and Stem Cell Legalities 
The US laws governing embryos and stem cells has varied considerably, depending on 
which elected president is in office, congress, and the people’s views and education about the 
subject matter.  In the US, the past few decades witnessed a suppression of hESC research. 
Since the development of human IVF techniques in the late 1960’s until now, the fate of the extra 
unwanted human embryos not used for reproduction has been debated.  According to Meredith 
Ebbin in her article “How other countries regulate stem cell clinics,” top US scientists 
acknowledge the ethical issues involved in ES cell research, but they confirm that the public 
discussion on ES cells in the US is sometimes based on misinformation and emotionally charged 
discussions (Ebbin, 2006). 
In 1973 Roe v Wade, the United States Supreme Court legalized certain types of 
abortions, allowing fetal tissue to be used for research purposes (Roe v Wade, 1973). This 
Supreme Court decision fueled the onset of endless ethical debates surrounding abortion 
(Morales, 2009). In 1979, President Carter, because of continued pressure from anti-abortion 
groups, disbanded the Health and Human Services Department advisory board that examined 
federally funded research on human sperm, eggs, and embryos (Smith, 1989).  As the anti-
abortion movement continued, political pressure continued to build, forcing President Ronald 
Reagan, and later George Bush, to block federal funding for research on human embryos.  
 
The Clinton Administration 
Stem cell research in the US is strongly linked with the politics of abortion.  Bill 
Clinton’s stance on abortion was clear, as he writes “Everyone knows life begins biologically at 
conception. No one knows when biology turns into humanity…I thought then [in the 1973 Roe 
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v. Wade decision] and still believe that the Court reached the right conclusion” (Clinton, 2004).  
To a large extent, Clinton also supported stem cell research.  In 1993, under President Clinton, 
the US Congress enacted the NIH Revitalization Act, giving NIH authority to fund human 
embryo research for the first time (Dunn, 2005). The NIH then established a panel to consider 
the moral and ethical issues involved, and to determine which embryos should receive federal 
funding.  In 1994, this NIH Human Embryo Research Panel (HERP) made its recommendations 
to President Clinton, permitting the funding of stem cells derived from excess IVF embryos from 
fertility clinics (Dunn, 2005).  
Due to public outrage, Clinton rejected some of the recommendations made by HERP, 
and informed NIH not to fund any research involving the creation of new embryos solely for 
research.  In response to further criticism, in 1995, Congress enacted the Dickey-Wicker 
Amendment which banned all embryo research (Robertson, 2010). Ever since, Congress has 
continually renewed the ban each year. 
 
The Bush Administration 
Under the presidency of George W. Bush, stem cell research witnessed severe 
oppression.  Coming from a conservative Christian background, Bush opposed hESC research, 
stating “While we must devote enormous energy to conquering disease, it is equally important 
that we pay attention to the moral concerns raised by the new frontier of human embryo stem cell 
research. Even the most noble ends do not justify any means.” (President George W. Bush's 
address on stem cell research, 2001).  The election of republican George W. Bush as President, 
with a republican majority in the House of Representatives, gave conservatives the upper hand.  
On August of 2001, President Bush extended congresses’ Dickey-Wicker ban to cover all hESCs, 
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with the exception of those cell lines created prior to his announcement (House, 2001).  This 
meant that federal funding would now be restricted to only those cell lines created before his 
announcement.  But the viability and pluripotency of these cell lines have raised a lot of 
questions. This decision stopped support to many promising avenues of biomedical research in 
an effort not to "sanction or encourage further destruction of human embryos" (Dunn, 2005). 
Within months, Bush further ordered an official removal of funding guidelines that Clinton had 
initially authorized. Thus, Bush became the first president to reduce the amount of hESC 
research eligible for federal funding. 
President Bush let his ethical belief get in the way of his decisions, and he continued to 
veto all legislations aimed at loosening the ban on hESC research.  He used his first veto power 
as a president after about 5.5 years in office against a stem cell bill, saying that the Senate’s Stem 
Cell Research Enhancement Act of 2005 "crossed a moral boundary" (Bash and Walsh, 2006).  
The bill, which the Senate had passed 63-37, would have loosened the restrictions on federal 
funding for stem-cell research.  In 2007, President Bush vetoed a second bill, similar in content 
to the previous Senate bill, claiming that scientific advances now allow researchers to pursue the 
potentially lifesaving work without destroying human embryos. In his message to Congress after 
the veto, Bush stated “The Congress has sent me legislation that would compel American 
taxpayers, for the first time in our history, to support the deliberate destruction of human 
embryos" (Fletcher, 2007).  
Bush’s stance against hESC research was not largely reflected by the US public.  
According to a 2007 Gallup Poll (Figure-1), even though about 64% of Americans said that 
Bush should not veto the stem cell bill earlier that year (Carroll, 2007), he still did, saying that 
the legislation crossed an ethical line.  
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Figure-1: Public Support of Stem Cells 2007.  A Gallup Poll in 2007 
shows that 64% of Americans were against Bush vetoing the stem cell 
bill in 2007.  (Carroll, 2007) 
 
 
US States Response to Bush Policies 
          As the federal funding of hESC research under Bush decreased, individual states passed 
laws funding private institutions for continuing the research.  In an effort to keep and attract top 
scientists and biomedical researchers, individual states in the US under Bush were forced to find 
ways of keeping stem cell research alive. Several US states launched campaigns against the 
national policy that limited federal funding to the previously derived hES cell lines (Figure-2).  
To date, states like California, New Jersey, New York, Massachusetts, Illinois, Maryland, 
Connecticut and Wisconsin are leading the way with both political and financial support 
(Wadman, 2008).  
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Figure-2:  Individual US State Embryonic Stem Cell Research 
Policies. The map shows the distribution of state stances on stem cell 
research. This figure points to the states that are leading the research with 
the most amount of finanacial support, as well as states that prohibit the 
practice. (Wadman, 2008) 
 
          As seen in figure-2 above, California tops the list financially. In 2004, California passed 
proposition 71, with the support of 59% of California voters. This bill provided 3 billion dollars, 
over the course of 10 years, to advance stem cell research in the state (Hayden, 2008). However, 
they were not the first state to spend state money for funding the research. Earlier in the same 
year, New Jersey was the first state to spend public money to fund ES cell research by 
appropriating $10 million for the research, including the building of the Stem Cell Institute of 
New Jersey. But California’s large scale funding encouraged many other states to follow on a 
similar path. According to Christine Vestal in “States take sides on stem-cell research,” States 
such as New York, Connecticut, Illinois, Maryland, Wisconsin and Massachusetts took a similar 
path, funding the research as well.   
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          In June 2005, Connecticut Governor M. Jodi Rell signed a measure providing $100 million 
in state funding over 10 years for embryonic stem cell research (Vestal, 2008).  Following that in 
the same year, Illinois Gov. Rod Blagojevich directed the public health department to grant $10 
million to stem-cell projects over 10 years, before adding $5 million more to the fund in July 
2006.  Also, Gov. Robert Ehrlich of Maryland signed a measure in 2006 appropriating $15 
million in to be distributed in 2007. Following the loss of his election, first-term Gov. Martin 
O’Malley then appropriated an extra $23 million for distribution in 2008.  Furthermore, 
Wisconsin Gov. Jim Doyle created $750 million investment fund to build the Wisconsin Institutes 
for Discovery, which will house the research facility for embryonic stem cell studies. The state of 
New York also signed a budget measure in 2007 that sets aside $600 million for stem-cell 
research over the span of 11 years under Gov. Eliot Spitzer, and Massachusetts Governor Deval 
Patrick proposed a $ 1 billion package to promote life sciences and stem cell research in the state 
(Vestal, 2008). 
          It was not surprising that Massachusetts, the home of leading research institutions like 
Harvard, MIT, and the University of Massachusetts Medical School, and a hub for biomedical 
research from Worcester to Boston, followed on a similar path.  Headed by Senate President 
Robert Travaglini in 2005, the senate passed a bill to promote stem cell research in the state, 
while at the same time explicitly banning human reproductive cloning, and established penalties 
for those who abuse it (Finer, 2005).  But the republican governor at the time, Mitt Romney, 
vetoed the bill claiming it would allow the cloning of human embryos—a practice that he termed 
as “morally wrong” (Romney, 2011).  But this action did not sit well with the state senate, and the 
bill was vetoed, overriding the Governor’s veto 35 to 2.  In 2007, under the new leadership of 
Massachusetts Governor Deval Patrick, in an effort to promote the state’s already existing global 
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leadership in the life sciences, he proposed a $1 billion state investment package. This package 
will provide grants for university and hospital scientists, train and cultivate talent for the 
biotechnology business, and establish research centers in the area ensuring the state’s ability to 
support the progress of life sciences and cutting edge biomedical research. Governor Patrick’s 
plan was very important for the scientific community, especially after Governor Romney’s 
previous opposition towards ES cell research. State legislators were supportive of Patrick’s plan, 
and it was approved in June of 2008.  The highlight of this effort was the establishment of the 
nation’s largest embryonic stem cell bank at the University of Massachusetts Medical School in 
Worcester. The Massachusetts Human Stem Cell Bank will be a 15,000 square foot facility that 
cultures, characterizes and provides hESCs to the research community globally. This investment 
turned out to be even bigger, when the University of Massachusetts Human Stem Cell Bank and 
Registry and the United Kingdom Stem Cell Bank signed an agreement in March of 2011. The 
agreement, which was part of Governor Patrick’s Innovation Economy Partnership Mission will 
allow both facilities to share best practices for stem cell banking and to collaborate on standards 
for stem cell line characterization, production, and distribution in the US and UK (Fessenden, 
2011). This is an important step to promote stem cell research in Massachusetts, and as Governor 
Patrick said, “the future of life sciences is here in Massachusetts… We have the talent. We have 
the entrepreneurial spirit. Now let’s seize the future” (Patrick, 2007).  
          Although the list of US states supporting ES cell research is growing, the number remains 
low overall. Some states like Iowa and Missouri have legalized the research, but have not 
provided any funding.  Other states such as Arkansas, Indiana, Louisiana, Michigan, North 
Dakota and South Dakota have restricted the practice. But the issue remains unsettled in much of 
the country, and the majority of the states have no legislations addressing ES cell research.  
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Even though state funding is not a replacement for larger amounts of federal money, such money 
will make a difference in the progress of stem cell research, and ultimately in the lives of those 
who carry hope. 
 
Current Obama Administration Policies 
          While the future of hESC research is uncertain, the present looks promising. In 2009, the 
inauguration of President Barak Obama, a democrat, opened new doors to hESC research in the 
United States. Within months of his presidency, Obama used his executive order to lift the 
restrictions on federal funding for responsible research involving hESCs.  This ended an 8½-year 
ban on federal funding for embryonic stem cell research under the Bush Administration.  
President Obama shows support for ES cell research and science in general, promising that his 
administration will make “scientific decisions based on facts, not ideology" (Childs and Stark, 
2009).  As part of his speech before signing the order, he said “We will lift the ban on federal 
funding for promising embryonic stem cell research…We will vigorously support scientists who 
pursue this research. And we will aim for America to lead the world in the discoveries it one day 
may yield" (Childs and Stark, 2009). The most immediate outcome of this promise will allow 
federally funded researchers to use hundreds of new embryonic stem cell lines for research in 
hopes of creating better treatments, possibly even cures, for many of man’s worst health 
conditions (Borenstein and Feller, 2009).   
          This presidential decision appears to be supported by the majority of the American people 
according to a 2009 Gallup poll (Figure-3) (Morales, 2009). The poll shows that 38% of 
Americans said they support easing Bush’s restrictions, and another 14% said they favor no 
restrictions at all. 
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Figure-3:  Public Support of Stem Cell Research in 2009.  A Gallup 
Poll conducted in February of 2009 showed that majority of Americans 
(52%) supported Obama’s easing Bush’s restriction or lifting restrictions 
entirely on hESCs.  (Morales, 2009) 
 
           Obama’s new legislation holds a lot of promise for stem cell research. The NIH estimates 
the number of newly allowed hESC lines to be anywhere from 400 to 1000. These lines are vastly 
different from the 21 or so originally eligible for federal funding under the previous Bush 
administration. 
          The new legislation, however, is governed by guidelines created by the NIH, to ensure the 
hESC research complies with ethical standards.  For instance, only excess embryos derived from 
IVF clinics are to be used to derive hESC lines. Also, the donor must provide informed consent 
before the embryo can be used for research. Furthermore, money cannot be used to pay or bribe 
individuals to donate their embryos solely for research. But despite the ethical guidelines, federal 
funding can be used to support hESC research, and that was welcoming news to scientists, and 
many supporters of hESC research. Former first lady Nancy Reagan, who rose to become a 
prominent supporter of stem cell research after the death of her husband, former President Ronald 
 49 
Reagan, from a 10-year battle with Alzheimer's, said that she is "very grateful" that Obama has 
reversed the federal government's policy on embryonic stem cell research funding. "These new 
rules will now make it possible for scientists to move forward… We owe it to ourselves and to 
our children to do everything in our power to find cures for these diseases -- and soon" Reagan 
added (Childs and Stark, 2009). 
 
International Stem Cell Policies 
          At the international level, hESCs have gathered both support and opposition.  In Europe, 
laws on stem cell research vary widely, with the United Kingdom being one of the biggest 
supporters, and Germany enforcing a near total ban.  In 2006, Germany, and the widely Roman 
Catholic Italy, strongly opposed the research, and tried to put pressure on other European 
countries to reject a proposal that will allow EU money to fund stem cell research in other EU 
countries.  Alongside Germany, Austria, Poland, Slovakia, Slovenia, Lithuania, Luxembourg, 
and Malta strongly opposed that EU should provide money from the science budget for 2007 to 
2013, to support projects in some countries if the same research is prohibited in other sister 
countries (Welle, 2006).  In fact, Germany and Italy banned any new extractions of ES cells from 
human embryos. However in July of 2006, the legislative body of the EU passed legislation 
allowing the funding of hESC research (Welle, 2006). 
          Countries like United Kingdom, China, Australia, Sweden, South Korea, Singapore and 
Japan, are actively involved in stem cell research. As seen in Figure-4, the governments of these 
countries (dark brown in the diagram) are very permissive and flexible to the research.  
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Figure-4: World Stem Cell Policies.  Shown is a world map with 
various countries in color depending on their stem cell policies.  Dark 
brown areas denote countries with permissive and flexible policies, 
allowing most forms of ES cell research. This region represents 3.8 
billion people. Yellow denotes countries with no stem cell policy in 
place. Light brown shows countries that have moderate policies 
governing the research. These countries mostly allow embryonic stem 
cell research from IVF embryos (Hoffman, 2005). 
 
          The United Kingdom has long been a major player in bioscience and Europe’s leader in 
stem cell research. In 2004, England became the third country in history to allow scientists to 
clone hESCs openly for research through somatic nuclear transfer (Ralston, 2008).  In 2005, a 
team of British scientists was the first in the world to successfully clone blastocysts (early stage 
embryos). Britain became the first country to legalize cloning, allowing scientists to make cloned 
embryos for stem cell research. In England, scientists can destroy donated embryos for stem cell 
research, and can create embryos by IVF.  The Government believes that stem cell research 
offers enormous potential to deliver new treatments for currently incurable diseases. As such, the 
government is working hard to promote the research, and has taken initiatives like establishing 
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the Human Fertilization and Embryology Authority to investigate and direct ES cell research. 
The government strives to make sure UK is in the forefront of stem cell research. 
Sweden is also considered a leader in stem cell research. With a well-established biomedical 
industry, the Swedish government provides funding to a large number of stem cell researchers. In 
2002, the Swedish government further authorized the creation of Europe's second stem cell bank 
(Ralston, 2008).  
          China has one of the most unrestrictive stem cell policies. In 2003, guidelines were issued 
by the Chinese government regulating the research because of the international criticism 
received, but China continues to permit researchers to conduct clinical trials in which terminally 
or chronically ill patients receive stem cell therapy (Ralston, 2008).  Interestingly, life begins at 
birth according to the Chinese culture, yet they still support embryo and hESC research. Other 
countries such as Canada, Brazil, India, Russia, Belgium, and South Africa are also taking part in 
stem cell research, but with less involvement and more moderate policies.      
          As other countries around the world progress in the stem cell field, some scientists fear the 
US will fall behind unless it expands federal funding to include therapeutic cloning.  The United 
States has the most potential in this field because of its leading institutions and ability to pay 
financially, however politics and ethics have worked against the progress of hESC research in 
the country.  But under president Obama, the future of the country in this important field of 
science appears promising. 
 
Chapter-4 Conclusions 
          Stem cell research, especially hESC research is a highly controversial topic, both 
politically and ethically. Thus, many governments around the world have enacted laws to 
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regulate it.  In this chapter, the laws regulating embryo and hESC research in different countries, 
including the US and its individual states, were discussed.  The chapter also explored how 
political views strongly influence the progress of science and discovery.  Over the past several 
decades, hESC research was generally suppressed in the US, forcing individual states to take on 
duties historically performed by the federal government and NIH into their own hands, and 
funding private institutions to conduct the research. This situation highlights the dynamics and 
power of the US legislative systems as it relates to science.  Although alternatives to hESCs 
exist, including adult stem cells and induced pluripotent cells, these cells hold less promise to 
mankind, as they are harder to isolate and grow.  Thus the quest to purse hESC research 
continues, with a hope for politicians to put ideology aside in this matter. President Barack 
Obama took a prime step to end the 8.5 years ban on federal funding for the research under Bush, 
presenting a hopeful future to the US and the outside world in this area of science. As Sean 
Morrison, the director of the University of Michigan Center for Stem Cell Biology in Ann Arbor 
said “President Obama's executive order signals a new day in which science policy will be based 
on science… America will once again seek to be the world's engine for biomedical discovery, 
leading the way toward new treatments for disease" (Childs and Stark, 2009). 
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PROJECT CONCLUSIONS 
 
 
  
Stem cell research, and especially embryonic stem (ES) cell research, brings both 
controversy and promise.  The authors of this paper, based on the research performed in this 
project, now provide their own personal conclusions.  All three authors agree that stem cell 
research is extremely important, and believe funding should be increased for it.  After all, some 
stem cell applications have already been proven to save lives in humans. With respect to 
embryos, one author sees that destroying an embryo should be avoided. Thus, adult stem cells 
(ASCs) and induced pluripotent stem (iPS) cells should be used as a replacement therapy 
whenever possible. The group as a whole, however, shares the opinion that excess embryos from 
IVF reproductive clinics should be used for ES research rather than embryos from paid donors. If 
women were allowed to donate their embryos for ES cell research in exchange for a monetary 
compensation, some women needing money might violate their own ethical beliefs and act as 
donors.  Using money as an incentive for people to donate their embryos would compromise the 
science and the true meaning of the research.  
As far as laws regulating embryo use, all three authors agree that the research should be 
governed by guidelines, ensuring that ethical boundaries are not crossed.  Thus, to a large extent, 
we agree that the Unites States under the Obama administration currently has acceptable policies 
in place governing stem cell research, and tend to think the policies of England, Sweden and 
China go too far in allowing SCNT cloning.  The current tight US guidelines on creating 
acceptable ES cell lines could be loosened to further stimulate ES cell research.  The authors 
applaud US states such as New Jersey, California, and Massachusetts, on their efforts for 
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keeping ES cell research alive by approving state bonds to fund private institutes.  These efforts, 
as well as others, will help promote regenerative medicine and help find answers to currently 
incurable human diseases.  Stem cell research should be given a chance, and the promise it 
carries should be the driving force. 
 
 
